Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBloating is one of the most commonly reported experiences in the first weeks on Wegovy. Semaglutide slows the rate at which food leaves your stomach, and that delayed gastric emptying can cause a full, gassy, distended feeling that catches many people off guard. It is a recognised side effect of semaglutide, typically most noticeable after starting or moving to a higher dose, and for most people it settles within a few weeks as the body adjusts. Wegovy is a prescription-only medicine; a prescriber assesses whether it is clinically appropriate for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide activates GLP-1 receptors in the gut and brain. One downstream effect is that food sits in the stomach longer than it ordinarily would. That is partly why appetite drops: signals of fullness persist well past a meal. The same mechanism, though, means gas accumulates, the stomach wall stretches, and the characteristic bloated feeling follows.
A misconception worth clearing up: some people assume the bloat means the medicine is not working, or that something is wrong. In most cases it is the opposite. The GI effects and the appetite effects share the same root cause. The gut is adapting to a genuinely new hormonal environment.
The Wegovy overview covers how semaglutide works more fully if you want the broader picture. For bloating specifically, knowing the mechanism helps because it tells you what to change and what to leave alone. You cannot remove the cause without removing the treatment; you can reduce the intensity by adjusting the things that compound it.
The NHS medicines page for semaglutide lists bloating, nausea, constipation and indigestion as commonly reported side effects, and notes they are generally most pronounced in the early weeks of each dose level. That matches what patients consistently report in clinical practice.
Several day-to-day habits interact directly with gastric emptying speed, and they are the variables you can act on. Eating quickly introduces air and places a sudden volume load on a stomach that is already working slowly. Smaller meals eaten at a steadier pace give the gut more manageable batches to process. That is not a dietary prescription; it is a practical observation worth testing.
Carbonated drinks contribute gas at exactly the point where your stomach has the least capacity to move it through quickly. Cutting them out (or at least reducing them in the first weeks at a new dose) is one of the more straightforward adjustments. High-fat meals also delay emptying further, compounding the effect of the medicine itself.
Fibre is worth a specific mention. A modest amount supports gut motility; a sudden large increase in fibre intake when the gut is already adjusting can make bloating worse rather than better. Gradual changes, not overhauls, tend to work better in practice. If constipation is accompanying the bloat, the detail on bloating and its associated symptoms explores that relationship further.
Physical activity, even light walking after eating, supports gastric motility. It does not need to be structured exercise to have an effect on how quickly discomfort clears.
Ordinary Wegovy bloating is uncomfortable but self-limiting. It does not typically worsen progressively after the first fortnight at a dose, and it improves with the practical measures above. There are, however, patterns that sit outside that description and should prompt contact with a healthcare professional rather than self-management.
Severe stomach pain, particularly pain that radiates toward the back, is not bloating. In January 2026 the MHRA issued a Drug Safety Update drawing attention to acute pancreatitis as an infrequent but serious risk with GLP-1 medicines; the key symptom is persistent, severe abdominal pain that may spread to the back, with or without vomiting. That warrants same-day medical attention, not dietary adjustment.
Equally, bloating that arrives alongside significant vomiting, inability to keep fluids down, or signs of dehydration needs clinical review. The page on gas and bloating on Wegovy covers the side-effect profile in more detail, including what to report to your prescriber. The MHRA Yellow Card scheme at yellowcard.mhra.gov.uk allows patients to report suspected side effects directly, which supports ongoing safety monitoring for medicines like Wegovy.
If you are weighing up whether the side effects are manageable alongside the treatment benefits, that is a clinical conversation, not one to resolve by stopping the medicine without advice. Our clinical team reviews this regularly with patients, and what happens if you stop Wegovy is something worth understanding before making that call.
Most people find bloating manageable once they know what to expect and have adjusted a few habits. The most effective sequence is usually: slow meals, smaller portions, cut carbonated drinks, avoid high-fat foods in the first few weeks at each new dose, and give the gut four to six weeks to settle before concluding that the pattern is permanent.
If you are considering starting Wegovy and wondering whether the early side effects are worth it, strategies for reducing bloating on Wegovy sets out the practical options in more depth. For cost context, the Wegovy pricing page covers what private treatment involves. And if you are not yet started, the right first step is a clinical assessment with a qualified prescriber who can look at your full picture before treatment begins.
Check your eligibility and speak to our prescribers by starting a free consultation with nume.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.